CRISPR-Cas13b-mediated suppression of HBV replication and protein expression
- Author(s)
- McCoullough, LC; Fareh, M; Hu, W; Sozzi, V; Makhlouf, C; Droungas, Y; Lee, CL; Takawy, M; Fabb, SA; Payne, TJ; Pouton, CW; Netter, HJ; Lewin, SR; Purcell, DF; Holmes, JA; Trapani, JA; Littlejohn, M; Revill, PA;
- Details
- Publication Year 2024-11,Volume 81,Issue #5,Page 794-805
- Journal Title
- Journal of Hepatology
- Publication Type
- Research article
- Abstract
- BACKGROUND & AIMS: New antiviral approaches that target multiple aspects of the HBV replication cycle to improve rates of functional cure are urgently required. HBV RNA represents a novel therapeutic target. Here, we programmed CRISPR-Cas13b endonuclease to specifically target the HBV pregenomic RNA and viral mRNAs in a novel approach to reduce HBV replication and protein expression. METHODS: Cas13b CRISPR RNAs (crRNAs) were designed to target multiple regions of HBV pregenomic RNA. Mammalian cells transfected with replication competent wild-type HBV DNA of different genotypes, a HBV-expressing stable cell line, a HBV infection model and a hepatitis B surface antigen (HBsAg)-expressing stable cell line were transfected with PspCas13b-BFP (blue fluorescent protein) and crRNA plasmids, and the impact on HBV replication and protein expression was measured. Wild-type HBV DNA, PspCas13b-BFP and crRNA plasmids were simultaneously hydrodynamically injected into mice, and serum HBsAg was measured. PspCas13b mRNA and crRNA were also delivered to a HBsAg-expressing stable cell line via lipid nanoparticles and the impact on secreted HBsAg determined. RESULTS: Our HBV-targeting crRNAs strongly suppressed HBV replication and protein expression in mammalian cells by up to 96% (p <0.0001). HBV protein expression was also reduced in a HBV-expressing stable cell line and in the HBV infection model. CRISPR-Cas13b crRNAs reduced HBsAg expression by 50% (p <0.0001) in vivo. Lipid nanoparticle-encapsulated PspCas13b mRNA reduced secreted HBsAg by 87% (p = 0.0168) in a HBsAg-expressing stable cell line. CONCLUSIONS: Together, these results show that CRISPR-Cas13b can be programmed to specifically target and degrade HBV RNAs to reduce HBV replication and protein expression, demonstrating its potential as a novel therapeutic option for chronic HBV infection. IMPACT AND IMPLICATIONS: Owing to the limitations of current antiviral therapies for hepatitis B, there is an urgent need for new treatments that target multiple aspects of the HBV replication cycle to improve rates of functional cure. Here, we present CRISPR-Cas13b as a novel strategy to target HBV replication and protein expression, paving the way for its development as a potential new treatment option for patients living with chronic hepatitis B.
- Publisher
- Elsevier
- Keywords
- *Hepatitis B virus/genetics/physiology; *Virus Replication/genetics; Humans; Animals; *CRISPR-Cas Systems; Mice; Hepatitis B/virology/genetics; RNA, Viral/genetics; Hepatitis B Surface Antigens/genetics/metabolism; Gene Expression Regulation, Viral; CRISPR-Cas13; Hepatitis B virus; Rna; hepatitis B surface antigen
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1016/j.jhep.2024.05.025
- Open Access at Publisher's Site
https://doi.org/10.1016/j.jhep.2024.05.025- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-07 06:54:31
Last Modified: 2024-11-07 06:54:57